SATORI
SATORI
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to Methotrexate.
The Satori Trial evaluated 125 patients with active rheumatoid arthritis (RA) with an inadequate response to low dose Methotrexate (MTX). Patients were allocated to receive either tocilizumab 8 mg/kg every 4 weeks (tocilizumab group) or MTX 8 mg/week (control group) for 24 weeks.
Summary of Results:
The ACR20, 50 and 70 response at week 24 was 80.3%, 49.2% and 29.5% in the tocilizumab group compared with 25.0%, 10.9% and 6.3% in the control group respectively. The DAS remission was observed in 43.1% patient in the tocilizumab group and 1.6% patient in the control group. Tocilizumab treatment also significantly improved MHAQ (Modified Health Assessment Questionnaire) scores compared to MTX treatment. The mean serum VEGF (Vascular Endothelial Growth Factor) levels showed a marked decrease in the tocilizumab group (mean change -346.9 pg/ml from baseline as compared to -74.0 pg/ml in the control group).
ACTEMRA monotherapy was well tolerated and provided an excellent clinical benefit in active RA patients with an inadequate response to low dose MTX.
Change in DAS score in two groups
Reference:
Norihiro Nishimoto et al. Mod Rheumatol (2009) 19:12–19